

**Supplemental Table 2: Cladribine Studies in Pediatric AML**

Study	Number of Patients	Median Age (years)	Study Design	Cladribine Dose	Cladribine Regimen Details	Outcome	Common Adverse Events
Santana et al (1992)	N=24	11 (3-19)	Phase II trial	8.9mg/m2/d	<u>Continuous for 5 days</u>	CR: 47% PR: 12%	Grade ≥ 3 Neutropenia Grade ≥ 3Thrombocytopenia
Rubnitz et al (2009)	N=96	9 (0.05-21)	Phase III trial	9 mg/m2/dose	<u>Arm A:</u> 5 days cladribine, cytarabine (500mg/m2/dose) over 2 hours.  <u>Arm B:</u> 5 days cladribine, cytarabine continuous infusion (500 mg/m2/d)	Arm A:43% Arm B: 65%	Grade ≥ 3 toxicity more in Arm B (48%) compared to Arm A ( 24%)
Inaba et al (2010)	N=26	10 (1-19)	Phase I trial	8.9mg/m2/d	5 days cadribine and topotecan (4mg/m2/d)*	CR: 34.6% PR : 61.5%	Febrile neutropenia
Chaleff et al (2012)	N=104	9.2 (0.9-20.4)	Phase II	8mg/m2/d	5 days cladribine 3 days idarubicin(10mg/m2/d)	CR: 46% PR: 5%	Grade ≥ 3 Neutropenia Grade ≥ 3Thrombocytopenia

**Abbreviation:** Complete remission (CR) , partial remission (PR) , day(d)  
 \*Topotecan was individualized after day 1 to target systematic exposure of 140 ±20mg/ml.hr